Tesaro gets a green light for rolapitant, triggering Merck showdown

John Carroll

The FDA has given a to start marketing to help prevent some of the common side effects of chemotherapy. And now will wage a David-vs.-Goliath battle for market share with a dominant .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS